BLCO Stock: Price, Earnings History and SEC Filings
Bausch + Lomb Corporation (BLCO) last traded at $20.00, down 1.96% on the latest session and up 17.6% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $0.34 against an analyst estimate of $0.21, a beat of 61.9%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
BLCO earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 28, 2026 | $0.34 | $0.21 | +61.90% |
| Jun 2026 | Jul 29, 2026 | $0.16 | $0.16 | +0.00% |
| Mar 2026 | Apr 29, 2026 | $0.08 | $0.06 | +33.33% |
| Dec 2025 | Feb 18, 2026 | $0.32 | $0.35 | -8.57% |
BLCO beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
How BLCO reacts to earnings
Across its last 8 earnings releases, BLCO moved 5.7% on average the next session, in either direction. It rose after 2 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-10-28 | Before open | +15.78% |
| 2026-07-29 | Before open | -2.47% |
| 2026-04-29 | Before open | -2.42% |
| 2026-02-18 | Before open | -0.34% |
| 2025-10-29 | Before open | +1.78% |
| 2025-07-30 | Before open | -6.42% |
| 2025-04-30 | Before open | -15.74% |
| 2025-02-19 | Before open | -0.31% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
BLCO financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $5.1B | -$360M | -$66M | -7.1% | $-1.02 |
| 2024 | $4.8B | -$317M | -$59M | -6.6% | $-0.90 |
| 2023 | $4.1B | -$260M | -$198M | -6.3% | $-0.74 |
| 2022 | $3.8B | $6M | $170M | 0.2% | $0.02 |
| 2021 | $3.8B | $182M | $680M | 4.8% | $0.52 |
| 2020 | $3.4B | -$18M | $269M | -0.5% | $-0.05 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for BLCO
- 8-K · Oct 28, 2026Officer or director change
- 10-Q · Oct 28, 2026
- 8-K · Oct 28, 2026Results of operations, Financial statements and exhibits
- 8-K · Oct 13, 2026Officer or director change, Regulation FD disclosure, Financial statements and exhibits
- 8-K · Aug 6, 2026Material agreement, Officer or director change, Other events
- 10-Q · Jul 29, 2026
- 8-K · Jul 29, 2026Results of operations, Financial statements and exhibits
- 8-K · May 20, 2026Shareholder vote
- 10-Q · Apr 29, 2026
- 8-K · Apr 29, 2026Results of operations, Financial statements and exhibits
Insider filing activity
BLCO insiders filed 12 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
BLCO news
- 1 cash-producing stock on our buy list and 2 that underwhelmOct 30, 2026 · finance.yahoo.com
- Bausch + Lomb (BLCO) Q3 Earnings Mark A Clear Profit TurnOct 30, 2026 · finance.yahoo.com
- Bausch Health Soars 21% on Beat-and-Raise Quarter: Core EBITDA Hits a “First Time” MilestoneOct 29, 2026 · tikr.com
- BHC Q3 Earnings Beat on Salix Growth, Stock Gains 9% as Outlook RisesOct 29, 2026 · finance.yahoo.com
- Bausch + Lomb Announces Publication of Multinational Survey Results Highlighting the Burden of Dry Eye Symptoms and Opportunities for Improved Awareness and Patient EducationOct 29, 2026 · finance.yahoo.com
- What Bausch + Lomb (BLCO) Said on Its Q3 Earnings CallOct 29, 2026 · marketbeat.com
- Bausch + Lomb (BLCO) stock trades up, here is whyOct 29, 2026 · finance.yahoo.com
- What Bausch Health Cos (BHC) Said on Its Q3 Earnings CallOct 29, 2026 · marketbeat.com
About Bausch + Lomb Corporation
Bausch + Lomb Corporation (BLCO) is a US-listed public company on NYSE. The SEC classifies its business as Ophthalmic Goods. Its fiscal year ends in December.